top of page
October 9, 2018
Appili Therapeutics Appoints Seasoned Infectious Disease Global Drug Development Executive Dr. Theresa Matkovits to Its Board of Directors
Read More
October 1, 2018
Appili Therapeutics Appoints Veteran Drug Development Executive, Dr. Armand Balboni, as Its Inaugural Chief Scientific Officer
Read More
August 16, 2018
Appili Therapeutics Announces Results of 2018 Annual and Special Meeting
Read More
July 30, 2018
Appili Therapeutics Completes Phase 1 Study for ATI-1501, Its Taste-Masked Oral Metronidazole Suspension
Read More
June 21, 2018
Appili Therapeutics to Present at 2018 Atlantic Venture Forum Technology Showcase
Read More
April 18, 2018
Appili Therapeutics to Present at 2018 Bloom Burton & Co. Healthcare Investor Conference
Read More
February 7, 2018
Appili Therapeutics Raises an Additional $4.3 Million in Oversubscribed Financing to Advance its Anti-infective Pipeline
Read More
January 26, 2018
Appili Recognized as ‘New Business of the Year’ by the Halifax Chamber of Commerce
Read More
January 9, 2018
Appili Therapeutics Licenses BioTerrorism Vaccine Rights
Read More
bottom of page